Canaccord Genuity Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Generic Copaxone Trial -- Day 2
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $27.00.
Canaccord analyst, Ritu Baral, said, "We think sales of m-enox, MNTA/Sandoz’s generic Lovenox, are strong but Teva’s (Nasdaq: TEVA) generic enox is still a threat. We think M356, MNTA/Sandoz’s generic Copaxone, is approvable without large trials and fall’s infringement suit will be positive for MNTA. We think MNTA will be a biosimilars development leader."
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $17.10 yesterday.
Canaccord analyst, Ritu Baral, said, "We think sales of m-enox, MNTA/Sandoz’s generic Lovenox, are strong but Teva’s (Nasdaq: TEVA) generic enox is still a threat. We think M356, MNTA/Sandoz’s generic Copaxone, is approvable without large trials and fall’s infringement suit will be positive for MNTA. We think MNTA will be a biosimilars development leader."
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $17.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Clear Street Reiterates Buy Rating on Anterix Inc. (ATEX)
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
